Shigeki Gondo
Kyushu University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shigeki Gondo.
Environmental Health Perspectives | 2007
Wu Qiang Fan; Toshihiko Yanase; Hidetaka Morinaga; Shigeki Gondo; Taijiro Okabe; Masatoshi Nomura; Tomoko Komatsu; Ken-ichirou Morohashi; Tyrone B. Hayes; Ryoichi Takayanagi; Hajime Nawata
Background Atrazine is a potent endocrine disruptor that increases aromatase expression in some human cancer cell lines. The mechanism involves the inhibition of phosphodiesterase and subsequent elevation of cAMP. Methods We compared steroidogenic factor 1 (SF-1) expression in atrazine responsive and non-responsive cell lines and transfected SF-1 into nonresponsive cell lines to assess SF-1’s role in atrazine-induced aromatase. We used a luciferase reporter driven by the SF-1–dependent aromatase promoter (ArPII) to examine activation of this promoter by atrazine and the related simazine. We mutated the SF-1 binding site to confirm the role of SF-1. We also examined effects of 55 other chemicals. Finally, we examined the ability of atrazine and simazine to bind to SF-1 and enhance SF-1 binding to ArPII. Results Atrazine-responsive adrenal carcinoma cells (H295R) expressed 54 times more SF-1 than nonresponsive ovarian granulosa KGN cells. Exogenous SF-1 conveyed atrazine-responsiveness to otherwise nonresponsive KGN and NIH/3T3 cells. Atrazine induced binding of SF-1 to chromatin and mutation of the SF-1 binding site in ArPII eliminated SF-1 binding and atrazine-responsiveness in H295R cells. Out of 55 chemicals examined, only atrazine, simazine, and benzopyrene induced luciferase via ArPII. Atrazine bound directly to SF-1, showing that atrazine is a ligand for this “orphan” receptor. Conclusion The current findings are consistent with atrazine’s endocrine-disrupting effects in fish, amphibians, and reptiles; the induction of mammary and prostate cancer in laboratory rodents; and correlations between atrazine and similar reproductive cancers in humans. This study highlights the importance of atrazine as a risk factor in endocrine disruption in wildlife and reproductive cancers in laboratory rodents and humans.
Genes to Cells | 2004
Shigeki Gondo; Toshihiko Yanase; Taijiro Okabe; Tomoko Tanaka; Hidetaka Morinaga; Masatoshi Nomura; Kiminobu Goto; Hajime Nawata
Bone marrow stem cells develop into haematopoietic and mesenchymal lineages, but have not been known to participate in steroidogenic cell production. Steroidogenic factor 1 (SF‐1), also designated adrenal 4 binding protein (Ad4BP), is an essential orphan nuclear receptor for steroidogenesis as well as for adrenal and gonadal gland development. In the present study, we revealed that the adenovirus‐mediated forced expression of SF‐1 can transform cultured primary long‐term cultured bone marrow cells into steroidogenic cells, showing the de novo synthesis of multiple steroid hormones in response to adrenocorticotropic hormone (ACTH). This finding may provide an initial step in innovative autograft cell transfer therapy for steroid hormone deficiencies.
Endocrinology | 2008
Shigeki Gondo; Taijiro Okabe; Tomoko Tanaka; Hidetaka Morinaga; Masatoshi Nomura; Ryoichi Takayanagi; Hajime Nawata; Toshihiko Yanase
Steroidogenic factor 1 (SF-1)/adrenal 4 binding protein is an essential nuclear receptor for steroidogenesis, as well as for adrenal and gonadal gland development. We have previously clarified that adenovirus-mediated forced expression of SF-1 can transform long-term cultured mouse bone marrow mesenchymal cells (BMCs) into ACTH-responsive steroidogenic cells. In the present study, we extended this work to adipose tissue-derived mesenchymal cells (AMCs) and compared its steroidogenic capacity with those of BMCs prepared from the identical mouse. Several cell surface markers, including potential mesenchymal cell markers, were identical in both cell types, and, as expected, forced expression of SF-1 caused AMCs to be transformed into ACTH-responsive steroidogenic cells. However, more elaborate studies revealed that the steroidogenic property of AMCs was rather different from that of BMCs, especially in steroidogenic lineage. In response to increased SF-1 expression and/or treatment with retinoic acid, AMCs were much more prone to produce adrenal steroid, corticosterone rather than gonadal steroid, testosterone, whereas the contrary was evident in BMCs. Such marked differences in steroidogenic profiles between AMCs and BMCs were also evident by the changes of steroidogenic enzymes. These novel results suggest a promising utility of AMCs for autologous cell regeneration therapy for patients with steroid insufficiency and also a necessity for appropriate tissue selection in preparing mesenchymal stem cells according to the aim. The different steroidogenic potency of AMCs or BMCs might provide a good model for the clarification of the mechanism of tissue- or cell-specific adrenal and gonadal steroidogenic cell differentiation.
Journal of Molecular Endocrinology | 2007
Tomoko Tanaka; Shigeki Gondo; Taijiro Okabe; Kenji Ohe; Hisao Shirohzu; Hidetaka Morinaga; Masatoshi Nomura; Kenzaburo Tani; Ryoichi Takayanagi; Hajime Nawata; Toshihiko Yanase
Steroidogenic factor 1/adrenal 4 binding protein (SF-1/Ad4BP) is an essential nuclear receptor for steroidogenesis as well as for adrenal and gonadal gland development. Mesenchymal bone marrow cells (BMCs) contain pluripotent progenitor cells, which differentiate into multiple lineages. In a previous study, we reported that adenovirus-mediated forced expression of SF-1 could transform mouse primary long-term cultured BMCs into steroidogenic cells. For future clinical application, trials using human BMCs would be indispensable. In this study, we examined whether SF-1 could transform human BMCs into steroidogenic cells and compared the steroid profile of these cells with that of mouse steroidogenic BMCs. Primary cultured human BMCs infected with adenovirus containing bovine SF-1 cDNA could produce progesterone, corticosterone, cortisol, dehydroepiandrosterone, testosterone, and estradiol. Such a mixed character of adrenal and gonadal steroid production in human BMCs was supported by the expressions of P450scc, 3beta-hydroxysteroid dehydrogenase (3beta-HSD), P450c21, P450c11, P450c17, 17beta-HSD, and P450arom mRNAs. Unlike mouse steroidogenic BMCs, introduction of SF-1 into human BMCs caused dramatic inductions of both ACTH and LH receptors, thus leading to good responsiveness of the cells to ACTH and LH respectively. Importantly, among several factors that are known to be closely associated with adrenal and/or gonadal development, introduction of only SF-1 enabled the human BMCs to express P450scc and to produce cortisol and testosterone, suggesting that SF-1 is truly a master regulator for the production of steroidogenic cells from human BMCs.
Biochemical and Biophysical Research Communications | 2008
Hisao Shirohzu; Taijiro Okabe; Shigeki Gondo; Tomoko Tanaka; Kenji Ohe; Hidetaka Morinaga; Hisaya Kawate; Masatoshi Nomura; Ryoichi Takayanagi; Hajime Nawata; Toshihiko Yanase
The mechanism for the steroidogenic tissue or cell-specific expression of SF-1 has not been well clarified. We examined whether the methylation status of a large CpG island in the first intron of mouse SF-1 gene is associated with the expression level of SF-1 in cultured cells and in tissues. The island consists of three small islands (ICI-1, ICI-2, and ICI-3). In cultured adrenocortical Y-1 cells and in Leydig tumor cells, I-10, that both express high levels of SF-1, the upstream region of ICI-2, ICI-2-1, was clearly hypomethylated compared to cultured mouse bone marrow cells that do not express SF-1. However, this methylation status was not clearly associated with the tissue-specific expression of SF-1, in either adult or during development. These results suggest that methylation of ICI-2-1of SF-1 may partly determine the level of SF-1 expression at the cellular level, but may not be essential at the tissue level.
Geriatrics & Gerontology International | 2018
Motoko Tago; Jun-ichi Oyama; Yoshiko Sakamoto; Aya Shiraki; Fumi Uchida; Atsuko Chihara; Hideo Ikeda; Shigetaka Kuroki; Shigeki Gondo; Taketo Iwamoto; Yasufumi Uchida; Koichi Node
The aim of the present study was to assess the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus.
Biochemical and Biophysical Research Communications | 2007
WuQiang Fan; Toshihiko Yanase; Hidetaka Morinaga; Shigeki Gondo; Taijiro Okabe; Masatoshi Nomura; Tyrone B. Hayes; Ryoichi Takayanagi; Hajime Nawata
Cardiovascular Diabetology | 2013
Yoshiko Sakamoto; Jun-ichi Oyama; Hideo Ikeda; Shigetaka Kuroki; Shigeki Gondo; Taketo Iwamoto; Yasufumi Uchida; Kazuhisa Kodama; Atsushi Hiwatashi; Mitsuhiro Shimomura; Isao Taguchi; Teruo Inoue; Koichi Node
Endocrine Journal | 2006
Toshihiko Yanase; Shigeki Gondo; Taijiro Okabe; Tomoko Tanaka; Hisao Shirohzu; WuQiang Fan; Koichi Oba; Hidetaka Morinaga; Masatoshi Nomura; Kenji Ohe; Hajime Nawata
Experimental Hematology | 2006
Tomoko Tanaka; Taijiro Okabe; Shigeki Gondo; Mitsue Fukuda; Masahiro Yamamoto; Tsukuru Umemura; Kenzaburo Tani; Masatoshi Nomura; Kiminobu Goto; Toshihiko Yanase; Hajime Nawata